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EnhancementLicensing and decisions on public health use of a vaccine rely on a robust clinical development program
that permits a risk-benefit assessment of the product in the target population. Studies undertaken early
in clinical development, as well as well-designed pivotal trials, allow for this robust characterization. In
2012, WHO published guidelines on the quality, safety and efficacy of live attenuated dengue tetravalent
vaccines. Subsequently, efficacy and longer-term follow-up data have become available from two Phase 3
trials of a dengue vaccine, conducted in parallel, and the vaccine was licensed in December 2015. The
findings and interpretation of the results from these trials released both before and after licensure have
highlighted key complexities for tetravalent dengue vaccines, including concerns vaccination could
increase the incidence of dengue disease in certain subpopulations. This report summarizes clinical
and regulatory points for consideration that may guide vaccine developers on some aspects of trial design
and facilitate regulatory review to enable broader public health recommendations for second-generation
dengue vaccines.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The first dengue vaccine (CYD-TDV or Dengvaxia, by Sanofi
Pasteur) was licensed in December 2015, after decades of researchand clinical development. Despite a significant global demand,
dengue vaccine development has been difficult for several reasons,
including the need for a tetravalent vaccine with efficacy against
each of the four dengue virus (DENV) serotypes, the lack ofnuated
Box 1 Points for consideration for the development of second-generation
live attenuated dengue vaccines.
 Early clinical studies are valuable to evaluate the potential
for interference between individual vaccine viruses and
the impact on the development of type-specific versus het-
erotypic immunity.
 Measuring antibody neutralization activity remains the
best method of defining dengue vaccine immunogenicity;
however, current assays do not easily distinguish between
type-specific antibodies, transient heterotypic antibody,
and long-lasting heterotypic antibody. Given this uncer-
tainty, the critical time point for assessment of immuno-
genicity as a correlate of durable protection should be
more than 12 months after the last vaccine dose. Various
research assays may be complementary.
 Controlled Human Infection Model (CHIM) trials can pro-
vide initial proof-of-concept that a vaccine may have
potential for clinical benefit, but greater confidence is
required in Dengue CHIM performance and challenge
should be complete 12 months or more after the last vac-
cine dose.
 For licensure, in the absence of an accepted correlate of
protection or risk, vaccine efficacy will need to be demon-
strated based on clinical outcomes collected over a multi-
year period (multiple dengue seasons) that support dur-
able benefit.
 Pre-vaccination and post-vaccination blood samples
should be collected and sera stored from all trial
participants.
 Dengue serostatus at baseline is a critical variable, and
safety and efficacy by serostatus should be presented in
a stratified analysis.
 Active surveillance used to assess efficacy against all den-
gue disease and severe dengue disease should be in place
preferably for at least 3–5 years after the last vaccine dose.
 Immunogenicity and efficacy results should be interpreted
in the context of potential transient heterotypic immunity
that could wane over time.
2 K.S. Vannice et al. / Vaccine xxx (2018) xxx–xxxrepresentative animal models, and concerns about vaccine-
induced immune enhancement as seen in natural infection [1,2].
While the successful registration of the first dengue vaccine repre-
sented a major milestone, there have also been setbacks. First, the
results of the multi-center pivotal Phase 3 trials highlighted impor-
tant limitations [3,4]. In these trials, in which three vaccine doses
were given separated by six months, efficacy varied according to
serotype, age and baseline dengue serostatus. Because a safety
signal was observed in young children in one of the trials during
longer-term follow-up, children below 9 years of age were subse-
quently excluded from the age-indication of this vaccine. In April
2016, the World Health Organization (WHO) recommended coun-
tries consider introducing the first licensed dengue vaccine only in
settings with a high burden of dengue disease, for the age group of
9–45 years, with seroprevalence criteria in the target age group for
vaccination of ideally >70% [5]. WHO issued this recommendation
due to limited evidence supporting the efficacy, safety, and long-
term performance of the vaccine in DENV-seronegative individuals
age >9 years, concerns about an excess risk of hospitalized dengue
in younger (2–5 years old) subpopulations, and lower efficacy in
DENV-seronegative subpopulations included in the current license
[6]. WHO and advisors called on the company to further
interrogate the clinical trial data and conduct additional targeted
studies to further analyze the issue of safety and risk for increased
incidence of symptomatic infection among vaccinated seronega-
tive persons, to be done as soon as possible [5–7]. A proposal for
the necessary post-licensure studies to address the question of
safety in seronegatives, including study designs, has been pub-
lished [8].
On November 29, 2017, Sanofi Pasteur announced that it had
used a new NS1 assay on sera taken after the 3rd dose and
imputation methods in order to classify participants retrospec-
tively into those likely to have been seronegative or seropositive
at the time of the first vaccine dose. These results were used to
estimate the long-term safety and efficacy of the vaccine by
serostatus prior to vaccination [9]. The company found an
increased risk of severe and hospitalized dengue associated with
vaccination among seronegatives. The company has stated its
intention to change the label so that individuals who have not
been previously infected by dengue virus should not be vacci-
nated. The WHO Global Advisory Committee on Vaccine Safety
and the WHO Secretariat published interim statements on
December 7, 2017 [10], and December 22, 2017 [11], respec-
tively. A full evidence review is now underway to revise the
WHO position.
In 2012, WHO issued guidelines on the regulation of dengue
vaccines, including their clinical development [12]. In light of the
experience of clinical development and of trying to formulate
evidence-based policy-making for the first licensed dengue vac-
cine, WHO convened a group of independent experts on March
21, 2017, to develop points for consideration for the clinical evalu-
ation of second-generation dengue vaccines. Here we summarize
the discussions and recommendations from this ad hoc consulta-
tion, which took place before the Sanofi Pasteur announcement,
but the points for consideration are all the more relevant in light
of the new information. These reflections, summarized in Box 1
may help vaccine developers, regulators and public health
decision-makers in planning studies or evaluating data on dengue
vaccines. It does not replace original WHO guidance [12], but
provides additional perspectives.Please cite this article in press as: Vannice KS et al. Clinical development and
dengue vaccines. Vaccine (2018), https://doi.org/10.1016/j.vaccine.2018.02.0622. Findings from the trials of the first-generation dengue
vaccine
The first licensed dengue vaccine, CYD-TDV or Dengvaxia, is a
recombinant live attenuated, tetravalent dengue vaccine based on
the yellow fever 17D vaccine backbone. The structural genes (prM-
E) of the YF17D virus vector are replaced by the structural genes of
each the four DENV serotypes. The initial license was typically with
an indication for individuals aged 9–45 years living in endemic
areas. Licensure was based on two large multicenter Phase 3 trials
conducted in Asia and Latin America with over 30,000 trial partic-
ipants; serostatus at baseline was assessed in a subset of about
2000 subjects in each trial [3,4,13]. A post hoc analysis stratifying
vaccine efficacy and safety by <9 and 9 years of age across all tri-
als led to the age indication starting at 9 years of age even though
two efficacy trials enrolled down to 2 or 4 years of age. CYD-TDV is
now registered in 19 countries [14].regulatory points for consideration for second-generation live attenuated
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lenged previously held ideas about how this vaccine protects and
the groups in whom protection might be greatest, and raised con-
cerns of late onset vaccine-associated enhanced disease, which
were later corroborated by the company’s new analysis.
(1) Balanced immunogenicity between dengue serotypes,
defined as a geometric mean neutralizing antibody titer
(GMT) as measured by standard plaque reduction neutral-
ization test (PRNT), did not correlate with serotype-specific
efficacy. In the Phase 3 trial in Asia, GMT measured 28 days
after the third vaccine dose were 166, 355, 207, and 151
against DENV1, DENV2, DENV3, and DENV4, respectively;
however, the respective vaccine efficacies were 54.5%,
34.7%, 65.2%, and 72.4% [3]. The highest GMT was raised
against DENV2, while for this serotype the vaccine efficacy
was the lowest; the reverse relationship was seen for
DENV4. Similar trends were seen in the Phase 3 trial in Latin
America [4]. A formal analysis of the relationship between
the level of neutralizing antibody at day 28 after the final
vaccine dose and subsequent risk of disease in the 13–25
months after the first dose has been published. While higher
neutralizing antibodies were shown to be associated with a
reduced risk of disease, there was no threshold by which
protection by CYD-TDV could be reliably predicted [15].
(2) Vaccine efficacy varied significantly by prior DENV infection
status [3,4]. In a post hoc, pooled analysis of the two Phase 3
trials, vaccine efficacy was 78.2% (95%CI 65.4%, 86.3%) in trial
participants who were DENV-seropositive at baseline (here-
after referred to as ‘‘seropositive”), and 38.1% (95%CI -3.4%,
62.9%) in trial participants who were DENV-seronegative at
baseline (hereafter referred to ‘‘seronegative”). In partici-
pants 9–16 years of age, vaccine efficacy in seronegatives
was 52.5% (95%CI 5.9%, 76.1%).
(3) In the third year of follow-up (12–24 months after the last
vaccine dose), participants aged 2–5 years in the Phase 3
trial in Asia had an increased risk of hospitalized dengue,
compared to the placebo group, with a relative risk (RR)
7.5 (95%CI 1.2, 313.8) [7,13]. Overall, the RR of hospitalized
dengue during the study based on data available as of Octo-
ber 2015, was 1.3 in the 2–5 year-old age group (95%CI 0.8,
2.1). The reason for this elevated risk in the 2–5 year age-
group was incompletely understood at the time of licensure.
One hypothesis proposed was that in seronegative individu-
als, the vaccine acts like an asymptomatic primary infection,
priming vaccinees to experience a ‘‘secondary-like” clinical
presentation upon a first natural exposure to DENV [16–
18]. While a DENV infection with a given serotype is thought
to provide lifelong protection against a second infection with
that serotype, second wildtype DENV infections of a differ-
ent serotype than the first are associated with more severe
clinical outcomes [19]. Serostatus was correlated with age
in the Phase 3 trials: in Asia, the proportion of participants
who were seropositive at the time of first vaccination was
51% for 2–5 year-olds, 72% among 6–11 year-olds and 81%
among 12–16 year-olds [3]. The findings of the additional
analyses announced in late November 2017 revealed that
the increased relative risk for more severe disease was inde-
pendent of age. The analysis confirmed that CYD-TDV pro-
vided persistent protective benefit against severe dengue
among seropositives, but for seronegatives, the analysis
found that in the longer term there was about two times
higher risk of more severe dengue and hospitalizations in
vaccinated participants [9,10].
(4) Follow-up analyses in a limited number of seronegative vac-
cinees suggest type-specific neutralizing responses werePlease cite this article in press as: Vannice KS et al. Clinical development and
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the protection of seronegative subjects observed against
DENV1, DENV2, and DENV3 may have resulted predomi-
nantly from heterotypic cross-protection, rather than type-
specific monotypic protection. If the heterotypic cross-
protection induced by vaccination is temporary, it may sup-
port the biologic mechanism for the increased risk seen ini-
tially in the 2–5 year-olds, the age group that had the
highest proportion of seronegatives, and subsequently in
seronegative participants of any age.
(5) Itwas also expected that thehighest protectionwouldbe seen
after subjects had received the full 3 doses of vaccine (‘‘per
protocol” analyses), but vaccine efficacywas found to be sim-
ilar for ‘‘intention to treat” analyses that included all cases
occurring after the first dose [3,4]. Whether this has implica-
tions for the ability of this or other live vaccines to boost the
immune response at a later stage is currently unknown.
The first dengue vaccine has significant limitations in relation to
large-scale public health use. An ideal dengue vaccine would offer
high protection against clinical disease due to any serotype and
would be similarly efficacious and safe regardless of prior DENV
infection and age at vaccination. Protection would ideally be long-
lasting, and vaccine-boosting of immunity should be possible if pro-
tection wanes over time. Additional dengue vaccine candidates are
currently in advanced clinical development, and regulators and pol-
icymakers will want to ascertainwhether or not second-generation
candidates share similarities to CYD-TDV. Below we outline some
considerations that may help with trial design and interpretation
of clinical trial results, as well as in licensing and use decisions. Sev-
eral of the considerations have already been integrated into ongo-
ing dengue clinical development programs.3. Learning from natural DENV infection
Tetravalent vaccination, representing simultaneous exposure to
the four DENV antigens, is fundamentally different from sequential
exposure to individual DENV serotypes through natural infection.
Nevertheless, it is important to consider aspects of live viral vacci-
nes through the lens of what is known about natural infection.
Firstly, the DENV serotypes are four genetically and serologically
distinct viruses [21]. A tetravalent vaccine, therefore, combines
four live vaccines, with risk of interference between the compo-
nents. Many years have been spent in early phases of live dengue
vaccine development attempting to find the right formulation to
overcome such interference [22].
Humoral immunity induced by infection with one DENV has
been characterized as homotypic against the infecting serotype
and heterotypic against the non-infecting other (and not previ-
ously seen) serotypes. While homotypic immunity is long-lasting,
heterotypic immunity that protects against non-infecting sero-
types is transient. It is believed that heterotypic immunity induced
after a primary wildtype DENV infection lasts about 1–2 years,
after which the individual is predisposed to more severe outcomes
associated with a second wildtype infection with another serotype
[23–25]. However, as 3rd and 4th DENV infections with different
serotypes are rarely associated with severe disease, and it is
assumed that heterotypic immunity following a second infection
is long-lasting [26]. Thus, it is important to distinguish between
transient and long-lasting heterotypic (also termed ‘‘multitypic”
[27]) immunity, the latter likely based on broadly cross-
neutralizing antibodies elicited by post-primary infections. Ideally,
a dengue vaccine should elicit long-lasting type-specific antibodies
against each of the four serotypes and/or long-lasting cross-
neutralizing heterotypic antibodies.regulatory points for consideration for second-generation live attenuated
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titers necessary for protection are higher than 1:10 [28,29], which
has been accepted as a correlate of vaccine-induced protection for
other flavivirus vaccines [30]. Thus, immunogenicity requirements
for a dengue vaccine may be higher than have been estimated for
other monovalent flavivirus vaccines, with the caveat that varia-
tions in laboratory assays inhibit a quantitative comparison
between titers against different flaviviruses. A further complication
is that thresholds of protection may vary by DENV serotype and by
candidate vaccine formulation. This poses a significant challenge to
assessing likely efficacy of second-generation dengue vaccines
based only on immunogenicity, as well as the use of immunogenic-
ity to bridge efficacy to populations not evaluated in clinical effi-
cacy trials.4. Considerations for early-stage clinical development of live
attenuated dengue vaccines
Early phase clinical studies can help characterize potential
interference between vaccine viruses, which influences whether
vaccine-induced immunity is serotype-specific or heterotypic for
each serotype. Additional characterization of vaccine candidates
using different assays and approaches can be complementary and
aid in de-risking late-stage development, helping to anticipate vac-
cine efficacy, longer-term protection, and safety in the field. None
of the studies outlined below need be considered on the critical
path to licensure but may bring added value in regulatory and
policy-making assessments.
4.1. Neutralization assays
The limitations of existing neutralization assays have been
described [29], but there are currently no validated alternatives.
Neutralization assays using sera collected shortly after vaccination
cannot distinguish between monotypic (long-lasting, type-
specific), transient heterotypic, or long-lasting heterotypic (multi-
typic) antibodies [27]. In addition, they may not measure antibod-
ies that may enhance infection. Therefore, any classical
measurement of neutralizing antibodies must be interpreted in
the context of time since exposure to infection or vaccination.
While repeated measurements over time may offer better charac-
terization of a post-vaccination immune response, the level(s) of
antibody required for robust protection is not yet known. Data
from any trial in which both pre-infection serological responses
and disease outcomes have been measured can be used to help
determine which assays should be further investigated for deter-
mining a correlate of protection.
There may be value in trying to optimize neutralization assays
to best reflect the immune response elicited by vaccination, such
as using Fcy-receptor bearing cells and measuring neutralization
using a variety of viral strains, including low-passage strains from
more recent clinical isolates. However, these modifications are still
considered exploratory. It is noted that non-neutralizing antibod-
ies may also contribute to protection; for instance, dengue NS1
interacts with the complement system and may directly contribute
to the vascular permeability syndrome, while antibodies to NS1
can confer protection by blocking its pathogenic effects [27,31].
4.2. Vaccine infectivity and interference
Live attenuated vaccines elicit human immune responses
through vaccine viral replication. Thus, for a tetravalent vaccine
to generate type-specific immune responses to each of the four ser-
otypes, it is thought that each of the four vaccine components
should replicate within the host. Demonstrating replication forPlease cite this article in press as: Vannice KS et al. Clinical development and
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when administered as a live tetravalent vaccine, is highly desirable
given the potential risk of interference.
The ability of vaccine viruses to replicate and the quality of
vaccine-induced immunity can be measured by multiple means,
and such studies are important to perform, at least initially, in a
flavivirus-naïve study population. Potential options include: (1)
recovering and quantifying vaccine virus through culture (e.g.
[32]); (2) detecting and quantifying viral RNA by RT-PCR (e.g.
[33]), ideally by detecting negative strand RNA since this indicates
viral replication, not just presence of vaccine virus; and (3) anti-
body depletion assays to determine whether type-specific
responses were generated for each of the four serotypes (e.g.
[20]). It is acknowledged that there are challenges with assay sen-
sitivity, and recovering and quantifying vaccine virus from each of
the four serotypes in an individual is a high bar. At a minimum,
indicating the proportion of a vaccinated group with detectable
replication of each vaccine virus provides basic characterization,
particularly when this is conducted serially over 14 days after the
first vaccine dose (e.g. [34]). The more evidence generated to sup-
port type-specific immune responses against the multiple vaccine
viruses, the more confidence regulators and policy makers may
have in their assessment of long-term efficacy and public health
utility.
Another approach has been to study immunogenicity of each
monovalent vaccine separately, as well as in combination, and to
compare levels of serotype-specific antibody. A problem with this
approach is the limitations of neutralization tests to measure
type-specific long-lasting protective antibody, especially at time
points close to vaccination. Furthermore, viral replication kinetics
of monovalent candidates may differ when formulated as a
tetravalent vaccine and it would be important to conduct studies
early in development defining these kinetics over a broad range
of days following vaccination. Longer-lasting antibodies, beyond
one year, may be more indicative of protection. Additionally, stud-
ies in non-human primates, especially challenge studies demon-
strating protection against viraemia at a meaningful time-point
(e.g., >12 months after the last vaccine dose), are of value, noting
limitations in extrapolating from the animal model to humans.
4.3. Controlled human infection model
Although not required as part of the critical path for vaccine
licensure, controlled human infection model (CHIM) trials can pro-
vide initial proof-of-concept that a vaccine is likely to have clinical
benefit, and this may de-risk decisions to evaluate candidates in
large Phase 3 efficacy trials. There is also the potential for dengue
CHIM to assist in the identification of an immune correlate of risk
or protection and potentially expand the indication for a vaccine.
There are currently both attenuated infection models (which do
not cause disease) and disease models [35]. In all models, the virus
is administered parenterally, which potentially confounds the
interpretation of outcomes, as the induction of infection via mos-
quito bite extends the incubation period and allows both innate
and adaptive immunity to condition the course of the infection.
The validity of efficacy measured by CHIM has yet to be estab-
lished, but an initial assessment can be made once efficacy results
from a Phase 3 trial are available for one vaccine candidate that has
also been evaluated by CHIM [36,37]. How well CHIM efficacy esti-
mates will predict efficacy against wild-type virus may also differ
between the infection and disease model.
Challenge strains have not yet been developed for all DENV ser-
otypes, which would be needed for a comprehensive assessment.
CHIM studies with each of the four serotypes would incur high
costs, and DENV serotypes for which there may be a priori concern
about interference, such as those with lower seroconversion rates,regulatory points for consideration for second-generation live attenuated
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in the interpretation of results due to the potential for short-lived
cross-protection. The longest time interval for a dengue CHIM
between vaccination and challenge is currently 3.5 years [38]. Ide-
ally, volunteers would be challenged at 12 months or greater after
vaccination, after transient heterotypic immunity would be
expected to have waned. Otherwise, it is possible that even high
efficacy demonstrated through CHIM could reflect the presence
of transient heterotypic protection.5. Considerations for late-stage clinical development
Until a surrogate or correlate of protection is established [30],
pivotal efficacy trials of dengue vaccines will need to be conducted
based on a clinical endpoint. The licensure of the first dengue vac-
cine introduces additional complexities to the design and site
selection for second-generation vaccine development and will
require close consultation with national regulatory authorities.
Efficacy trials of dengue vaccines have specified a primary end-
point of virologically-confirmed dengue of any severity due to any
serotype. Even with these broad endpoints, it has been necessary
to include 10,000–20,000 participants in trials to have statistical
power to demonstrate vaccine efficacy. Such trials have very high
cost and it is important that the designs of Phase 3 pivotal trials
are optimized based on lessons learned from the first pivotal trials.
The objectives of a clinical development program for a dengue
vaccine are likely to remain largely as outlined in the initial
WHO guidelines [12], with the addition of critical analyses of
immunological and clinical outcomes by pre-vaccination immune
status. Thus, the clinical evaluation of a candidate live tetravalent
dengue vaccine should document (1) the immune responses eli-
cited by the vaccine against each of the four DENV serotypes
according to pre-vaccination immune status; (2) vaccine efficacy
for the prevention of symptomatic dengue of any severity caused
by any DENV serotype over an appropriate minimum period of
observation (preferentially 5 years) according to pre-vaccination
dengue immune status; and (3) the safety profile according to
pre-vaccination immune status. As further outlined in the WHO
guideline, preliminary evidence should be gathered showing the
absence of a significant signal that the immediate and longer-
term immune response to a candidate dengue vaccine predisposes
vaccinated individuals (or a subset) to an increased risk of dengue
and/or severe dengue disease with subsequent natural infections,
relative to the control group. Finally, surrogate markers or immune
correlates of protection and/or risk should be defined [12].5.1. Immune status at vaccination
It is essential that a pivotal trial be designed so that vaccine effi-
cacy, safety, and duration of protection can be assessed by serotype
and serostatus. The finding of a substantially increased risk of hos-
pitalized dengue associated with vaccination of seronegatives in
the longer-term following the last dose of the CYD-TDV vaccine
[11] has led to increased focus on vaccine efficacy and safety in
seronegative populations. Biologically this is not surprising, as
serostatus is a strong modifier of immune responses, infection
and disease susceptibility, and vaccine take. It is now clear that
vaccine efficacy and clinical outcomes should always be evaluated
stratified by baseline neutralizing antibody to DENV. In some cases,
it may also be appropriate to consider the influence of prior infec-
tion with other prevalent flaviviruses [39,40].
It has been proposed, and it is generally accepted, that in future
Phase 3 trials of dengue vaccines, pre-vaccination and post-
vaccination blood samples should be collected and sera stored
from all trial participants, not just a subset [29]. Should testingPlease cite this article in press as: Vannice KS et al. Clinical development and
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unfeasible, testing a large subset or testing the prior stored sam-
ples for all cases would provide information on efficacy and safety
according to prior serostatus. To help characterize the immune
response generated by vaccination over time, blood samples
should be collected at different time points after vaccination, e.g.
between doses, after the last dose, 6 months after the last dose,
12 months after the last dose, and at 12-month intervals for the
duration of the trial and follow-up. Additionally, given that the role
of T cell immunity in vaccine-induced immunity remains unclear,
it is desirable to also collect PMBCs from as large a subset of partic-
ipants as possible for exploratory analyses.
In order to have sufficient seronegative trial participants to
characterize the risk/benefit in this subpopulation, the study pop-
ulation could be enriched for seronegative participants, or a trial
could be powered to demonstrate efficacy in seronegatives. In
the two Phase 3 trials of CYD-TDV, the incidence of virologically
confirmed dengue was similar in unvaccinated seronegatives and
seropositives (in the Asia trial, incidences of 4.3% (95%CI 2.5–6.6)
and 3.9% (95%CI 2.7–5.4) in seronegatives and seropositives,
respectively [3], and in the Latin American trial corresponding inci-
dences of 3.2% (95% 1.5–5.9) and 2.3% (1.5–3.5) [4]). The seropos-
itive population may have included some individuals who had
already experienced 2 or more infections at the time of vaccina-
tion, a group in which we would expect little additional public
health value for a vaccine given the low rate of disease associated
with tertiary and quaternary infections. In the same epidemiolog-
ical context as the Asian trial, 70% efficacy could be demonstrated
in seronegatives with as few as 1200 trial participants (1-sided
alpha = 2.5% and 90% power, lower limit of the 95%CI of 0).
Seronegative study participants could be identified by screening
using ELISA, which is less costly and labor-intensive than PRNT.
While available ELISA kits are not specific enough to determine
baseline seropositivity given the potential cross-reactivity with
other flaviviruses, they could be adequate to rule out prior expo-
sure to any flavivirus, including DENV.
5.2. Methods and duration of follow-up
If a live attenuated vaccine stimulates immunity similarly to
natural infection, replication of only one component in a tetrava-
lent vaccine may demonstrate efficacy against all serotypes for
the first 1–2 years after the last dose of vaccine [23–25]. Thus, vac-
cine efficacy estimates against each of the four serotypes generated
in a 12-month time frame after the last dose should be interpreted
in the context of potentially transient cross-protection. Twelve
months post-vaccination is a typical primary endpoint for pivotal
trials for other vaccines, but for DENV, a longer period of follow-
up is needed to establish both safety and the longer-term efficacy
over multiple dengue seasons, going beyond temporary cross-
protection. Hence, WHO guidelines recommend subjects to be
followed-up for safety and efficacy for at least 3–5 years from the
time of completion of primary vaccination [12]. Registration may
be sought on the basis of early follow-up data (e.g. 2 years after last
dose), but follow-up should continue with timely updates provided
to regulators throughout their assessment. It is important that the
same level of surveillance be maintained throughout the duration
of the study so that changes in vaccine efficacy over time can be
detected particularly as cross-protection wanes. To maintain the
integrity of the trial over this extended timeframe, trial partici-
pants and investigators who interact with the participants should
remain blinded unless there is an ethical obligation to inform par-
ticipants, such as in the post-licensure phase when and if there is a
national recommendation for vaccination. The method of case
detection should ideally remain unchanged (i.e., active surveil-
lance) to make meaningful comparisons over time. The primaryregulatory points for consideration for second-generation live attenuated
6 K.S. Vannice et al. / Vaccine xxx (2018) xxx–xxxendpoint for vaccine trials has typically been virologically-
confirmed dengue of any severity as measured by active surveil-
lance in order to have a manageable sample size, as hospitalized
or severe dengue is relatively rare. Capturing both dengue of any
severity as well as hospitalized and well-defined severe dengue
allows for an understanding of whether dengue illness presenta-
tion is modified by vaccination status, which may vary by time
since last vaccination. Clinical data should be carefully monitored
for any imbalance of symptomatic or severe dengue cases, includ-
ing in subpopulations, and in particular in the period following
expected cross-protection.
An extended follow-up period will also allow for additional
power to look at secondary analyses, such as sustained vaccine effi-
cacy by infecting serotype(s). It is desirable that clinical trial sites
are chosen such that there is circulation of each of the four sero-
types within the trial, likely requiring a geographically dispersed
multicenter study.6. Other regulatory and policy considerations
Registration and public health recommendations would be
facilitated by data that indicate presence of protective monotypic
responses against all vaccine strains, as well as vaccine efficacy
beyond the period of short-lived heterologous cross-protection,
which is likely beyond 12 months after the last dose administered.
Even if serotype-specific efficacy and efficacy in seronegatives are
not primary endpoints (as is the case for the two candidates cur-
rently in Phase 3 trials [37,41]), regulators may require data that
provide reassurance that the vaccine can be used safely and effec-
tively in the target population. Any public health recommenda-
tions for use should also take into account such data.
For some flaviviruses (e.g., Japanese encephalitis), immuno-
bridging has been accepted for licensing across vaccine candi-
dates/platforms; however, these vaccines are monovalent rather
than tetravalent. In the context of dengue vaccines, due to the lack
of clear understanding of mechanisms of protection and risk, the
variability in neutralization assays, the lack of assays that properly
distinguish various types of neutralizing antibody, and the likely
differences in elicited immunity by different dengue vaccine candi-
dates, immunobridging based on traditional PRNT may be ques-
tionable to regulators as the primary basis of licensure. Assays
able to measure serotype-specific long-lasting protective immu-
nity are critically needed. Currently, placebo-controlled efficacy
trials are still likely to be considered ethical and desirable in many
settings. WHO has provided guidance on ethical acceptability of
placebo-controlled trials in the context of the availability of a
licensed product [42].7. Conclusions
Our understanding of how dengue vaccines can decrease, or
increase, the risk of dengue disease is evolving. To ensure that reg-
ulatory and public health-decision makers can best and rapidly uti-
lize the vaccination tools that become available, a robust clinical
development program is needed that affords adequate characteri-
zation of a vaccine candidate’s benefit-risk profile over a period
of time sufficient to predict durable benefit. There are models for
joint regulatory assessments that may aid national regulatory
authorities with complex dossiers, and this was done for the first
licensed dengue vaccine [43]. Clinical data generated in the course
of a clinical development program should be made publicly avail-
able for regulators, policy-makers, and the broader community in a
timeframe consistent with WHO’s position on clinical trial results
reporting [44].Please cite this article in press as: Vannice KS et al. Clinical development and
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